UAE announces new veterinary medicine ban: What’s affected?
The Emirates Drug Establishment has ordered the withdrawal of nine veterinary products containing ciprofloxacin to combat antimicrobial resistance
20 October, 2026
TT
16
The UAE will ban the use of ciprofloxacin in its veterinary sector from November 1, 2026, as part of efforts to combat antimicrobial resistance and protect the effectiveness of antibiotics used in human medicine.
The Emirates Drug Establishment (EDE) announced that the prohibition will cover veterinary medicinal products and raw materials containing ciprofloxacin, an antibiotic belonging to the fluoroquinolone group.
The decision affects nine veterinary products, including eight imported products and one locally registered product.
The regulator has instructed relevant establishments to stop manufacturing, importing and supplying the affected products and withdraw existing stocks from the UAE market before the ban takes effect.
Remaining quantities must either be re-exported or disposed of in accordance with approved procedures.
Why is the UAE banning ciprofloxacin in veterinary medicine?
According to EDE, fluoroquinolones are classified as Critically Important Antimicrobials (CIAs) for human medicine because of their role in treating certain bacterial infections.
The regulator said inappropriate use of these antibiotics in animals could contribute to antimicrobial resistance, potentially reducing the effectiveness of treatments available for human patients.
The decision follows a scientific assessment of antimicrobial resistance data, including studies submitted by United Arab Emirates University.
The findings were used to support the regulatory decision and strengthen national measures aimed at limiting antibiotic resistance.
Dr Ruqaya Aqeel Al Bastaki, Acting Executive Director of the Medical Products Regulation Sector at EDE, said regulating antimicrobial use requires a risk-based approach that considers the potential impact of each substance on treatment priorities across different sectors.
She emphasised that scientific evidence plays a central role in determining when regulatory intervention is necessary.
Al Bastaki added that EDE remains committed to aligning its decisions with scientific developments to preserve treatment effectiveness, strengthen pharmaceutical security and protect public health.
Veterinary businesses ordered to withdraw affected products
Under the new requirements, establishments dealing with the affected veterinary medicines must complete the necessary withdrawal procedures before November 1.
Businesses will also be required to submit supporting documentation confirming that the products have been withdrawn and that remaining stocks have been re-exported or disposed of in accordance with approved procedures.
EDE said it has already identified the products and raw materials covered by the ban and notified the relevant establishments.
The regulator is also preparing a monitoring plan to assess compliance and verify that businesses complete the required procedures within the specified timeframe.
The decision forms part of EDE’s broader efforts to strengthen oversight of veterinary medical products and promote responsible antimicrobial use.
The authority said the measures would support national initiatives to combat antimicrobial resistance while helping safeguard both human and animal health.





















